Responses
Oncolytic and local immunotherapy
Original research
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
